{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,31]],"date-time":"2025-08-31T10:23:40Z","timestamp":1756635820459,"version":"3.37.3"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2021,10,8]],"date-time":"2021-10-08T00:00:00Z","timestamp":1633651200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,10,8]],"date-time":"2021-10-08T00:00:00Z","timestamp":1633651200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"name":"The Chronic Lymphocytic Leukemia Foundation"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1038\/s41375-021-01438-4","type":"journal-article","created":{"date-parts":[[2021,10,10]],"date-time":"2021-10-10T06:35:58Z","timestamp":1633847758000},"page":"712-722","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["RPPA-based proteomics recognizes distinct epigenetic signatures in chronic lymphocytic leukemia with clinical consequences"],"prefix":"10.1038","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1269-3273","authenticated-orcid":false,"given":"Anneke D.","family":"van Dijk","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4227-3870","authenticated-orcid":false,"given":"Ti\u2019ara L.","family":"Griffen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yihua H.","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fieke W.","family":"Hoff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Endurance","family":"Toro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kevin","family":"Ruiz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter P.","family":"Ruvolo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"suffix":"Jr","given":"James W.","family":"Lillard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eveline S. J. M.","family":"de Bont","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6177-7572","authenticated-orcid":false,"given":"Jan A.","family":"Burger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7357-270X","authenticated-orcid":false,"given":"William","family":"Wierda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5990-9548","authenticated-orcid":false,"given":"Steven M.","family":"Kornblau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,10,8]]},"reference":[{"key":"1438_CR1","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.1056\/NEJM199510193331606","volume":"333","author":"C Rozman","year":"1995","unstructured":"Rozman C, Montserrat E. Chronic lymphocytic leukemia. N. Engl J Med. 1995;333:1052\u20137.","journal-title":"N. Engl J Med"},{"key":"1438_CR2","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1182\/blood-2015-04-585067","volume":"126","author":"N Jain","year":"2015","unstructured":"Jain N, O\u2019Brien S. Initial treatment of CLL: integrating biology and functional status. Blood. 2015;126:463\u201370.","journal-title":"Blood"},{"key":"1438_CR3","doi-asserted-by":"publisher","first-page":"4088","DOI":"10.1200\/JCO.2010.33.9002","volume":"29","author":"WG Wierda","year":"2011","unstructured":"Wierda WG, O\u2019Brien S, Wang X, Faderl S, Ferrajoli A, Do KA, et al. Multivariable model for time to first treatment in patients with chronic lymphocytic leukemia. J Clin Oncol: Off J Am Soc Clin Oncol. 2011;29:4088\u201395.","journal-title":"J Clin Oncol: Off J Am Soc Clin Oncol"},{"key":"1438_CR4","doi-asserted-by":"publisher","first-page":"1859","DOI":"10.1182\/blood.2019003453","volume":"135","author":"A Condoluci","year":"2020","unstructured":"Condoluci A, Terzi di Bergamo L, Langerbeins P, Hoechstetter MA, Herling CD, De Paoli L, et al. International prognostic score for asymptomatic early-stage chronic lymphocytic leukemia. Blood. 2020;135:1859\u201369.","journal-title":"Blood"},{"key":"1438_CR5","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1182\/blood-2009-07-232868","volume":"115","author":"M Kanduri","year":"2010","unstructured":"Kanduri M, Cahill N, G\u00f6ransson H, Enstr\u00f6m C, Ryan F, Isaksson A, et al. Differential genome-wide array-based methylation profiles in prognostic subsets of chronic lymphocytic leukemia. Blood. 2010;115:296\u2013305.","journal-title":"Blood"},{"key":"1438_CR6","doi-asserted-by":"publisher","first-page":"567","DOI":"10.4161\/epi.20237","volume":"7","author":"L Pei","year":"2012","unstructured":"Pei L, Choi JH, Liu J, Lee EJ, McCarthy B, Wilson JM, et al. Genome-wide DNA methylation analysis reveals novel epigenetic changes in chronic lymphocytic leukemia. Epigenetics. 2012;7:567\u201378.","journal-title":"Epigenetics"},{"key":"1438_CR7","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1016\/j.ccell.2014.10.012","volume":"26","author":"DA Landau","year":"2014","unstructured":"Landau DA, Clement K, Ziller MJ, Boyle P, Fan J, Gu H, et al. Locally disordered methylation forms the basis of intratumor methylome variation in chronic lymphocytic leukemia. Cancer cell. 2014;26:813\u201325.","journal-title":"Cancer cell"},{"key":"1438_CR8","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1038\/leu.2012.245","volume":"27","author":"N Cahill","year":"2013","unstructured":"Cahill N, Kanduri M, Mansouri L, Sundstrom C, Rosenquist R, Ryan F, et al. 450K-array analysis of chronic lymphocytic leukemia cells reveals global DNA methylation to be relatively stable over time and similar in resting and proliferative compartments. Leukemia. 2013;27:150\u20138.","journal-title":"Leukemia"},{"key":"1438_CR9","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1038\/ng.2443","volume":"44","author":"M Kulis","year":"2012","unstructured":"Kulis M, Heath S, Bibikova M, Queir\u00f3s AC, Navarro A, Clot G, et al. Epigenomic analysis detects widespread gene-body DNA hypomethylation in chronic lymphocytic leukemia. Nat Genet. 2012;44:1236\u201342.","journal-title":"Nat Genet"},{"key":"1438_CR10","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1038\/leu.2014.252","volume":"29","author":"AC Queiros","year":"2015","unstructured":"Queiros AC, Villamor N, Clot G, Martinez-Trillos A, Kulis M, Navarro A, et al. A B-cell epigenetic signature defines three biologic subgroups of chronic lymphocytic leukemia with clinical impact. Leukemia. 2015;29:598\u2013605.","journal-title":"Leukemia"},{"key":"1438_CR11","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2015.14","volume":"5","author":"EN Smith","year":"2015","unstructured":"Smith EN, Ghia EM, DeBoever CM, Rassenti LZ, Jepsen K, Yoon K, et al. Genetic and epigenetic profiling of CLL disease progression reveals limited somatic evolution and suggests a relationship to memory-cell development. Blood Cancer J. 2015;5:e303.","journal-title":"Blood Cancer J"},{"key":"1438_CR12","doi-asserted-by":"publisher","first-page":"35946","DOI":"10.18632\/oncotarget.9371","volume":"7","author":"N Papakonstantinou","year":"2016","unstructured":"Papakonstantinou N, Ntoufa S, Chartomatsidou E, Kotta K, Agathangelidis A, Giassafaki L, et al. The histone methyltransferase EZH2 as a novel prosurvival factor in clinically aggressive chronic lymphocytic leukemia. Oncotarget. 2016;7:35946\u201359.","journal-title":"Oncotarget"},{"doi-asserted-by":"crossref","unstructured":"Rabello DdA, Lucena-Araujo AR, Alves-Silva JCR, Souza dEVBA, de Vasconcellos MC, de Oliveira FM, et al. Overexpression of EZH2 associates with a poor prognosis in chronic lymphocytic leukemia. Blood Cells Mol Dis. 2015;54:97\u2013102.","key":"1438_CR13","DOI":"10.1016\/j.bcmd.2014.07.013"},{"key":"1438_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.semcancer.2018.02.001","volume":"51","author":"L Mansouri","year":"2018","unstructured":"Mansouri L, Wierzbinska JA, Plass C, Rosenquist R. Epigenetic deregulation in chronic lymphocytic leukemia: Clinical and biological impact. Semin Cancer Biol. 2018;51:1\u201311.","journal-title":"Semin Cancer Biol"},{"doi-asserted-by":"crossref","unstructured":"van Dijk AD, Hu CW, de Bont, ESJM, Qiu Y, Hoff FW, Yoo SY, et al. Histone modification patterns using RPPA-based profiling predict outcome in acute myeloid leukemia patients. Proteomics. 2018;18:e1700379.","key":"1438_CR15","DOI":"10.1002\/pmic.201700379"},{"key":"1438_CR16","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1182\/blood-2020-139387","volume":"136","author":"AD van Dijk","year":"2020","unstructured":"van Dijk AD, Hoff FW, Qiu Y, de Bont ES, Bruggeman SWM, Horton TM, et al. Loss of H3K27 methylation identifies poor outcome in adult-onset acute myeloid leukemia. Blood. 2020;136:24.","journal-title":"Blood"},{"key":"1438_CR17","doi-asserted-by":"publisher","first-page":"2512","DOI":"10.1158\/1535-7163.MCT-06-0334","volume":"5","author":"R Tibes","year":"2006","unstructured":"Tibes R, Qiu Y, Lu Y, Hennessy B, Andreeff M, Mills GB, et al. Reverse phase protein array: validation of a novel proteomic technology and utility for analysis of primary leukemia specimens and hematopoietic stem cells. Mol cancer therapeutics. 2006;5:2512\u201321.","journal-title":"Mol cancer therapeutics"},{"key":"1438_CR18","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1007\/978-1-61779-286-1_10","volume":"785","author":"SM Kornblau","year":"2011","unstructured":"Kornblau SM, Coombes KR. Use of reverse phase protein microarrays to study protein expression in leukemia: technical and methodological lessons learned. Methods Mol Biol. 2011;785:141\u201355.","journal-title":"Methods Mol Biol"},{"key":"1438_CR19","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1182\/blood-2007-10-119438","volume":"113","author":"SM Kornblau","year":"2009","unstructured":"Kornblau SM, Tibes R, Qiu YH, Chen W, Kantarjian HM, Andreeff M, et al. Functional proteomic profiling of AML predicts response and survival. Blood. 2009;113:154\u201364.","journal-title":"Blood"},{"doi-asserted-by":"publisher","unstructured":"Hu CW, Kornblau SM, Slater JH, Qutub AA. Progeny clustering: a method to Identify Biological Phenotypes. Sci Rep. 2015. https:\/\/doi.org\/10.1038\/srep12894.","key":"1438_CR20","DOI":"10.1038\/srep12894"},{"key":"1438_CR21","first-page":"100","volume":"28","author":"JA Hartigan","year":"1979","unstructured":"Hartigan JA, Wong MAA. K-Means clustering algorithm. J R Stat Soc: Ser C (Appl Stat). 1979;28:100\u20138.","journal-title":"J R Stat Soc: Ser C (Appl Stat)"},{"doi-asserted-by":"crossref","unstructured":"Therneau PM. Modeling survival data: extending the Cox model. Springer; 2000.","key":"1438_CR22","DOI":"10.1007\/978-1-4757-3294-8"},{"unstructured":"Swerdlow SH, WHO Classification of tumors of haematopoietic and lymphoid tissues.4th ed. IARC; 2008.","key":"1438_CR23"},{"key":"1438_CR24","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.critrevonc.2016.06.003","volume":"104","author":"L Scarf\u00f2","year":"2016","unstructured":"Scarf\u00f2 L, Ferreri AJM, Ghia P. Chronic lymphocytic leukaemia. Crit Rev Oncol \/ Hematol. 2016;104:169\u201382.","journal-title":"Crit Rev Oncol \/ Hematol"},{"doi-asserted-by":"crossref","unstructured":"Kipps TJ, Fraser G, Coutre SE, Brown JR, Barrientos JC, Barr PM, et al. Long-Term Studies Assessing Outcomes of Ibrutinib Therapy in Patients With Del(11q) Chronic Lymphocytic Leukemia. Clin Lymphoma Myeloma Leuk. 2019;19:715\u201322.e6.","key":"1438_CR25","DOI":"10.1016\/j.clml.2019.07.004"},{"doi-asserted-by":"crossref","unstructured":"Burger JA, Barr PM, Robak T, Owen C, Ghia P, Tedeschi A, et al. Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL\/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study. Leukemia 2020;34:787\u201398.","key":"1438_CR26","DOI":"10.1038\/s41375-019-0602-x"},{"doi-asserted-by":"publisher","unstructured":"van Dijk AD, Hoff FW, Qiu YH, Chandra J, Jabbour E, de Bont, ESJM, et al. Loss of H3K27 methylation identifies poor outcomes in adult-onset acute leukemia. Clin Epigenet. 2021. https:\/\/doi.org\/10.1186\/s13148-021-01011-x.","key":"1438_CR27","DOI":"10.1186\/s13148-021-01011-x"},{"doi-asserted-by":"crossref","unstructured":"Li Y, Schulz VP, Deng C, Li G, Shen Y, Tusi BK, et al. Setd1a and NURF mediate chromatin dynamics and gene regulation during erythroid lineage commitment and differentiation. Nucleic Acids Res. 2016;44:7173\u201388.","key":"1438_CR28","DOI":"10.1093\/nar\/gkw327"},{"key":"1438_CR29","doi-asserted-by":"publisher","first-page":"2039","DOI":"10.1182\/blood-2013-03-486647","volume":"122","author":"BE Li","year":"2013","unstructured":"Li BE, Gan T, Ernst P, Meyerson M, Rabbitts TH. Distinct pathways regulated by menin and by MLL1 in hematopoietic stem cells and developing B cells. Blood. 2013;122:2039\u201346.","journal-title":"Blood"},{"key":"1438_CR30","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1096\/fj.14-263061","volume":"29","author":"BK Tusi","year":"2015","unstructured":"Tusi BK, Deng C, Salz T, Zeumer L, Li Y, So CWE, et al. Setd1a regulates progenitor B-cell-to-precursor B-cell development through histone H3 lysine 4 trimethylation and Ig heavy-chain rearrangement. FASEB J. 2015;29:1505\u201315.","journal-title":"FASEB J"},{"key":"1438_CR31","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1097\/MOH.0000000000000346","volume":"24","author":"W Yang","year":"2017","unstructured":"Yang W, Ernst P. Distinct functions of histone H3, lysine 4 methyltransferases in normal and malignant hematopoiesis. Curr Opin Hematol. 2017;24:322\u20138.","journal-title":"Curr Opin Hematol"},{"key":"1438_CR32","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1038\/ni876","volume":"4","author":"IH Su","year":"2003","unstructured":"Su IH, Basavaraj A, Krutchinsky AN, Hobert O, Ullrich A, Chait BT, et al. Ezh2 controls B cell development through histone H3 methylation and Igh rearrangement. Nat Immunol. 2003;4:124\u201331.","journal-title":"Nat Immunol"},{"key":"1438_CR33","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.chembiol.2014.11.021","volume":"22","author":"M Zhou","year":"2015","unstructured":"Zhou M. Small-Molecule Modulators of Methyl-Lysine Binding for the CBX7 Chromodomain. Chem Biol. 2015;22:161\u20138.","journal-title":"Chem Biol"},{"key":"1438_CR34","doi-asserted-by":"publisher","first-page":"3012","DOI":"10.1182\/bloodadvances.2018020065","volume":"2","author":"K Maharaj","year":"2018","unstructured":"Maharaj K, Powers JJ, Achille A, Deng S, Fonseca R, Pabon-Saldana M, et al. Silencing of HDAC6 as a therapeutic target in chronic lymphocytic leukemia. Blood Adv. 2018;2:3012\u201324.","journal-title":"Blood Adv"},{"key":"1438_CR35","doi-asserted-by":"publisher","first-page":"939","DOI":"10.4161\/cbt.8.10.8213","volume":"8","author":"W Fiskus","year":"2009","unstructured":"Fiskus W, Buckley K, Rao R, Mandawat A, Yang Y, Joshi R, et al. Panobinostat treatment depletes EZH2 and DNMT1 levels and enhances decitabine mediated de-repression of JunB and loss of survival of human acute leukemia cells. Cancer Biol Ther. 2009;8:939\u201350.","journal-title":"Cancer Biol Ther"},{"key":"1438_CR36","doi-asserted-by":"publisher","first-page":"3096","DOI":"10.1158\/1535-7163.MCT-06-0418","volume":"5","author":"W Fiskus","year":"2006","unstructured":"Fiskus W, Pranpat M, Balasis M, Herger B, Rao R, Chinnaiyan A, et al. Histone deacetylase inhibitors deplete enhancer of zeste 2 and associated polycomb repressive complex 2 proteins in human acute leukemia cells. Mol cancer therapeutics. 2006;5:3096\u2013104.","journal-title":"Mol cancer therapeutics"},{"key":"1438_CR37","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1002\/mc.22983","volume":"58","author":"DH Lee","year":"2019","unstructured":"Lee DH, Kim GW, Kwon SH. The HDAC6-selective inhibitor is effective against non-Hodgkin lymphoma and synergizes with ibrutinib in follicular lymphoma. Mol Carcinog. 2019;58:944\u201356.","journal-title":"Mol Carcinog"},{"key":"1438_CR38","doi-asserted-by":"publisher","first-page":"138","DOI":"10.4161\/epi.23439","volume":"8","author":"N Cahill","year":"2013","unstructured":"Cahill N, Rosenquist R. Uncovering the DNA methylome in chronic lymphocytic leukemia. Epigenetics. 2013;8:138\u201348.","journal-title":"Epigenetics"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41375-021-01438-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-021-01438-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-021-01438-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,28]],"date-time":"2022-02-28T09:03:16Z","timestamp":1646038996000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41375-021-01438-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,8]]},"references-count":38,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,3]]}},"alternative-id":["1438"],"URL":"https:\/\/doi.org\/10.1038\/s41375-021-01438-4","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"type":"print","value":"0887-6924"},{"type":"electronic","value":"1476-5551"}],"subject":[],"published":{"date-parts":[[2021,10,8]]},"assertion":[{"value":"20 May 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 September 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 September 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 October 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}